Showing results (31-40 of 99) with videos related to
Sort By:
Pageof 10
Molecular Immunology|May 18, 2007
Targeting of humanized antibody D93 to sites of angiogenesis and tumor growth by binding to multiple epitopes on denatured collagensBruce Freimark, Derek Clark, Flavia Pernasetti, et al.Mabs|May 10, 2023
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptorsKerry A Whalen, Kavya Rakhra, Naveen K Mehta, et al.Heart and Vessels|July 24, 2008
Myocardial gene expression of matched hibernating and control tissue from patients with ischemic left ventricular dysfunctionDietlind Zohlnhöfer, Thomas G Nührenberg, Felix Haas, et al.European Journal of Pharmacology|December 19, 2006
Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSFRuzica Puljic, Ewald Benediktus, Christine Plater-Zyberk, et al.Cancer Immunology, Immunotherapy : CII|March 24, 2010
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigenClaudia Bluemel, Susanne Hausmann, Petra Fluhr, et al.Immunobiology|January 23, 2009
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110Cornelia Haas, Eva Krinner, Klaus Brischwein, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2003
A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alphaAnnegret de Baey, Ines Mende, Gustavo Baretton, et al.International Immunology|March 22, 2005
Highly efficient antigen targeting to M-DC8+ dendritic cells via FcgammaRIII/CD16-specific antibody conjugatesInes Mende, Patrick Hoffmann, Andreas Wolf, et al.Molecular Immunology|November 7, 2006
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysisMichael Mølhøj, Sandrine Crommer, Klaus Brischwein, et al.Current Clinical Pharmacology|May 19, 2018
Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin LymphomaYoussef Hijazi, Matthias Klinger, Andrea Kratzer, et al.Pageof 10